Percheron Therapeutics (ASX:PER) advanced its phase 2b trial investigating the use of avicursen (ATL1102) in patients with Duchenne muscular dystrophy, according to a Monday filing with the Australian bourse.
All 48 patients from the randomized, placebo-controlled trial completed their 25th-week visit, with results expected by the week starting Dec. 16, the filing said. The trial's 12-month study data is anticipated for mid-2025.
The company's shares were down almost 3% in recent Monday trade.
Price (AUD): $0.07, Change: $-0.002, Percent Change: -2.70%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。